Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Scientists Find Link Between Nicotine, Type 2 Diabetes

By Drug Discovery Trends Editor | March 9, 2016

Researchers at Lund University in Sweden have made two new discoveries with regard to the beta cells’ ability to release insulin. The findings can also provide a possible explanation as to why smokers have an increased risk of type 2 diabetes.

The study was conducted on mice and donated beta cells from humans, and is now published in the scientific journal Cell Reports.

The researchers have discovered that so-called nicotinic acetylcholine (nicotine-sensitive) receptors influence the normal release of insulin. They also show that a specific genetic alteration renders dysfunctional nicotine-receptors affecting the number of functional nicotine-sensitive receptors found in beta cells. A reduced number of functional receptors leads to a decrease in insulin secretion, thereby increasing the risk of developing type 2 diabetes.

“The receptors in the beta cells that stimulate the release of insulin are normally activated by the signal substance acetylcholine, but they can also be activated by nicotine. Never before has the importance of nicotine-sensitive receptors been shown in terms of the function of beta cells. Our research indicates that people who lack these receptors are at higher risk of developing type 2 diabetes”, says Isabella Artner, researcher at Lund University responsible for the study.

Isabella Artner and her colleagues have also discovered that the gene MafA (muscoloaponeurotic fibrosacoma oncogene family A) found in insulin-producing beta cells control the number of nicotine-sensitive receptors and thereby their ability to receive signals from the central nervous system.

“The effect that this single gene, MafA, alone has on insulin secretion was previously unknown, and nicotine receptors have never before been connected to type 2 diabetes”, says Isabella Artner, and continues:

“We know that smokers have an increased risk of developing type 2 diabetes, but the reason why has not been firmly established. Perhaps it has to do with the nicotine-sensitive receptors we describe. Our findings increase knowledge about the connection between smoking and type 2 diabetes.

Source: Lund University


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50